A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
UCB Biopharma SRL
Study ID
NCT03347110
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Bimekizumab at a prespecified dose.

Study Details

This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis

Key Dates

Start date
Nov 22, 2017
Status verified
Nov 2023
Primary completion
Oct 29, 2020
Completion
Oct 29, 2020

Study Design

Enrollment
184 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Subjects will receive bimekizumab up to 2 years.

Primary Outcome Measure

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study [ Time Frame: From Entry Visit of PA0009 until Safety Follow-Up Visit (up to Week 120) ]

Locations (11)

FacilityCityStateZIPSite coordinators
Pa0009 025LexingtonKentucky40504-
Pa0009 003HagerstownMaryland21502-
Pa0009 011LansingMichigan48910-
Pa0009 028RochesterNew York14642-
Pa0009 014PortlandOregon97239-
Pa0009 001DuncansvillePennsylvania16635-
Pa0009 012JohnstonRhode Island02919-
Pa0009 004CharlestonSouth Carolina29406-
Pa0009 010JacksonTennessee38305-
Pa0009 006DallasTexas75231-
Pa0009 013MesquiteTexas75150-

Find similar trials in Lexington, KY

By condition
Psoriatic arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Pa0009 025· Lexington, KYPa0009 003· Hagerstown, MDPa0009 011· Lansing, MIPa0009 028· Rochester, NYPa0009 014· Portland, ORPa0009 001· Duncansville, PA

Related Studies